L'intérêt à découvert pour Inogen donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Inogen. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Inogen (NASDAQ:INGN) Stock, Rapport sur les intérêts à découvert

Inogen

Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.

Inogen Inc

Medical Technology company Inogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) reported a fourth-quarter adjusted EPS loss of 24 cents, compared to a loss of 83 cents a year ago, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss of 61 cents</a>.
The company reported sales of $80.1 million, beating the consensus of $73.9 million.
Total revenue in the fourth quarter of 2024 increased 5.5% year over year, primarily driven by higher demand and new customers in international and domestic business-to-business sales, partially offset by lower direct-to-consumer sales and lower rental revenue as a result of the company's initiatives to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43956475/inogen-announces-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">enhance overall profitability</a>.
"2024 was a stellar year for Inogen. With our new leadership team in place, we returned the company to growth, achieved significant milestones, and made meaningful steps towards profitability," said Kevin Smith, president and CEO. "With our leading portfolio of innovative respiratory care products, the pending introduction of Simeox in the U.S. and our recently announced collaboration with Yuwell, we believe we are well positioned to drive future growth, profitability, and sustained success."
Adjusted EBITDA loss was $3.6 million in the fourth quarter of 2024 compared to $17.3 million a year ago.
Guidance: Inogen expects first quarter 2025 sales of $79 million-$81 million versus consensus of $78.1 million.
The company expects fiscal year 2025 sales of $352 million-$355 million versus a consensus of $344.61 million.
Analyst Reaction:
<ul>
<li>JP Morgan writes, &#8220;With initial guidance for 1Q25 also starting off a step above the Street, we view today as another step forward towards what we hope to be fully normalized trends in 2H25 ahead of more meaningful contribution from strategic initiatives in 2026+.&#8221;</li>
<li>Analyst Robbie Marcus notes that while the company has a strong product in the underdeveloped POC market, its short-term outlook is uncertain. Supply challenges remain unresolved, and another sales team restructuring adds to the uncertainty.</li>
<li>JP Morgan maintains the Underweight rating with a <a href="https://www.benzinga.com/quote/INGN/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $10</a>.</li>
<li>Needham analyst Mike Matson reiterates Inogen with a Hold rating.</li>
<li>William Blair says, &#8220;Despite the softer DTC and rental segments, Inogen continues to see strength in its B2B segments in the U.S. and internationally. In our view, strength in this segment is durable and, although stepping down in 2025 off tougher comps, should continue to drive performance.&#8221;</li>
<li>Analyst Margaret Kaczor Andrew says the company is on a clear path to profitability and will soon benefit from recent management-driven changes in strategy, culture, and organization.</li>
</ul>
Price Action: INGN stock reached as high as $11.85 during the premarket trading before falling 9.45% to $8.60 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/02/43972083/amazons-25-billion-robotics-push-targets-cost-savings-ai-growth-and-temu-competition-report" target="_blank" rel="noreferrer noopener">Amazon&#8217;s $25 Billion Robotics Push Targets Cost Savings, AI Growth And Temu Competition: Report</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings

News

Guidance

Health Care

Analyst Ratings

Movers

Trading Ideas

General

INGN

What's Going On With MedTech Focused Inogen Stock On Wednesday?

Needham analyst Mike Matson reiterates Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Inogento Hold

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) sees FY2025 sales of $352.000 million-$355.000 million vs $344.61 million analyst estimate.

Inogen Sees FY2025 Sales $352.000M-$355.000M vs $344.61M Est

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) sees Q1 sales of $79.000 million-$81.000 million vs $78.08 million analyst estimate.

Inogen Sees Q1 Sales $79.000M-$81.000M vs $78.08M Est

WIIM

Inogen shares are trading higher after the company reported better-than-expected Q4 financial results.

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.61) by 60.66 percent. This is a 71.08 percent increase over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $80.08 million which beat the analyst consensus estimate of $73.91 million by 8.35 percent. This is a 5.51 percent increase over sales of $75.90 million the same period last year.

Earnings Beats

Inogen Q4 Adj $(0.24) Beats $(0.61) Estimate, Sales $80.08M Beat $73.91M Estimate

AHCO

ALLT

ARQT

AXGN

AXON

BASE

BGFV

BLZE

BTDR

BWIN

CART

CAVA

CBLL

CCCS

CECO

CGBD

CHRD

CIFR

CPNG

CPSS

DAWN

DNUT

DOCN

DRVN

ELAN

EXLS

FIHL

FLYW

FSLR

FULC

GPOR

HRMY

HSIC

HURN

HYLN

IART

ICCC

IGIC

IMOS

INTU

INVX

IPAR

ITRI

IVAC

JACK

JAZZ

KEYS

KNSA

LCID

LGIH

LIVN

LMND

LXFR

MASI

MATX

MFIC

MIDD

MMSI

MPLN

MRVI

NOVT

NXRT

Earnings Scheduled For February 25, 2025

The strategic collaboration is expected to broaden Inogen's product portfolio through distribution of certain respiratory products in the United States and select other territories, expand and enhance Inogen's innovation pipeline through R&amp;D collaboration, and accelerate the entry of Inogen's brand into the Chinese market. In addition, Yuwell, through its affiliate, has agreed to invest approximately $27.2 million in Inogen, representing a 9.9% common equity interest, further cementing the collaboration and bolstering Inogen's balance sheet.

Reported Sunday, Inogen And Yuwell Forge Strategic Collaboration To Broaden Global Reach And Develop Next-Generation Respiratory Solutions

<h3>Gainers</h3>
<ul>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock increased by 43.9% to $14.92 during Thursday's pre-market session. The market value of their outstanding shares is at $45.3 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares moved upwards by 42.88% to $0.19. The market value of their outstanding shares is at $1.3 million. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) shares increased by 13.54% to $0.8. The market value of their outstanding shares is at $60.3 million. </li>
<li>Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) shares moved upwards by 12.74% to $12.21. The company's market cap stands at $290.8 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares rose 12.53% to $0.29. The market value of their outstanding shares is at $21.0 million. </li>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) shares moved upwards by 12.31% to $2.28. The company's market cap stands at $93.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) shares fell 16.7% to $1.5 during Thursday's pre-market session. The company's market cap stands at $79.1 million. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) shares decreased by 14.53% to $3.06. The market value of their outstanding shares is at $101.2 million. </li>
<li>Channel Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares fell 11.48% to $2.39. The company's market cap stands at $14.4 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) shares fell 10.0% to $1.8. The company's market cap stands at $5.4 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) shares decreased by 8.98% to $0.4. The company's market cap stands at $7.0 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock fell 8.91% to $0.75. The market value of their outstanding shares is at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALXO

CHRO

HEPA

HSDT

INAB

JUNS

SONN

VIGL

XCUR

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Inogen Estimates Preliminary FY24 Total Revenue Of $334.5M - $335.5M (Est $329.615M), Exceeding Prior Guidance Range Of $329M - $331M

Inogen  Estimates Preliminary Q4 Total Revenue Of $79M - $80M, Reflecting YoY Growth Of 4% To 5%; Est $73.91M

SIMEOX 200 is the next-generation of the original Simeox (currently available in select international markets). It is intended to promote and improve bronchial drainage by enhancing mobilization of bronchial secretions via high frequency oscillatory vibrations and intermittent negative pressure to the airway during exhalation.
Inogen plans to pursue a limited launch of SIMEOX 200 in targeted sites in 2025.
 &nbsp;

Inogen Receives FDA 510(K) Clearance For SIMEOX 200 Airway Clearance Device

Inogen shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 revenue guidance.

Needham analyst Mike Matson reiterates Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) with a Hold.

Needham Reiterates Hold on Inogen

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) raises FY2024 sales outlook from $325.00 million-330.00 million to $329.00 million-331.00 million.

Inogen Raises FY2024 Sales Guidance from $325.00M-330.00M to $329.00M-331.00M

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.49) by 77.55 percent. This is a 69.44 percent increase over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $88.83 million which beat the analyst consensus estimate of $84.14 million by 5.58 percent. This is a 5.80 percent increase over sales of $83.97 million the same period last year.

Inogen Q3 Adj $(0.11) Beats $(0.49) Estimate, Sales $88.83M Beat $84.14M Estimate

Inogen, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ingn#NASDAQ">INGN</a>) is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid first-quarter 2024 performance and a strong product portfolio, seems justified. However, issues like stiff competition and forex volatility are major downsides.
The Zacks Rank #2 (Buy) company&#39;s shares have risen 106.4% year to date compared with 9.2% growth of the&nbsp;industry. The S&amp;P 500 has increased 17.7% during the same time frame.
The renowned provider of POCs has a market capitalization of $268.7 million. The company projects 56.6% growth for 2024 and expects to witness continued improvements in its business. Inogen&#39;s P/S ratio of 0.8X makes its valuation attractive compared with the industry&#39;s 3.1X.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/57/77823.jpg?v=1381474216" />
Image Source: Zacks Investment Research
Let us delve deeper.
High Prospects in the POC Space:&nbsp;We are optimistic about the POCs&#39; superiority over conventional oxygen therapy (known as the delivery model). Inogen primarily develops, manufactures and markets innovative POCs to deliver supplemental long-term oxygen therapy (LTOT) to patients suffering from chronic respiratory conditions.
INGN&#39;s proprietary Inogen One and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen anytime, anywhere, with a battery that can be plugged into an outlet. Per a report by Data Bridge Market Research, the POCs market was valued at $1.58 billion in 2022 and is anticipated to reach $3.03 billion by 2030 at a CAGR of 8.5%.
Product Portfolio:&nbsp;We are optimistic about Inogen&#39;s expanding product portfolio. The company has received the FDA 510(k) clearance for the Inogen Rove 4, which is set to be launched soon. The Rove 4 will offer patients a new flow setting compared to the earlier versions, a service life of up to eight years and highest oxygen production. It is also the lightest POC in the market.
Inogen launched Rove 6 in the U.S. market in July 2023. The Inogen Rove 6 is the first POC with an expected service life of eight years.
Strong Q2 Results: Inogen&#39;s robust year-over-year uptick in domestic and international business-to-business sales buoys optimism. Solid year-over-year top and bottom-line performances were encouraging. Further, the expansion of the adjusted gross margin bodes well.
On the earnings call, management confirmed that targeting hospitals in addition to individual practitioners through its rental business gave earlier access to patients in their care pathway, increasing the duration over which INGN can receive payments. By expanding its scale, efficiency and throughput in the rental channel, Inogen expects to drive higher profitability over time.
The company is also seeing cost benefits in the form of lower sales and marketing expenses on the back of the recent exit of its third-party relationship in the rental channel. These factors raise optimism about the stock.
<h2>Risks</h2>
Stiff Competition:&nbsp;The LTOT market has intense industrial competition. Inogen faces competition from several POC producers and distributors as well as suppliers of other LTOT services, such as home delivery of oxygen cylinders or tanks. Given the relatively straightforward regulatory path in the oxygen therapy device manufacturing market, Inogen expects the industry to become increasingly competitive in the future.
Forex Volatility:&nbsp;The foreign market accounts for a sizeable amount of INGN&#39;s income. &nbsp;Management anticipates overseas revenues to continue to be erratic due to the distributor&#39;s size and timing. In the near future, INGN also expects unfavorable foreign exchange rates to hinder revenue growth since the U.S. dollar is increasing relative to the euro and other foreign currencies.
<h2>Estimate Trend</h2>
Inogen has been witnessing an improving estimate revision trend for 2024. In the past 60 days, the Zacks Consensus Estimate for its loss per share has narrowed 11.4% to $1.95.
The Zacks Consensus Estimate for 2024 revenues is pegged at $327 million, suggesting a 3.6% decline from the year-ago reported number.
<div class="chart_embed">
<h3>Inogen, Inc Price</h3>
<img alt="Inogen, Inc Price" src="https://staticx-tuner.zacks.com/images/charts/18/1726483416.png" style="height:251px; width:571px" title="" />
Inogen, Inc price | Inogen, Inc Quote
</div>
<h2>Key Picks</h2>
Some other top-ranked stocks in the broader medical space are Boston Scientific, AxoGen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) and SiBone (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sibn#NASDAQ">SIBN</a>), each carrying a Zacks Rank #2 at present.
Boston Scientific&#39;s shares have risen 58.4% in the past year. Estimates for the company&#39;s earnings per share have remained constant at $2.40 for 2024 and $2.71 for 2025 in the past 30 days. BSX&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for AxoGen&#39;s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 145% in the past year compared with the industry&#39;s growth of 15.5%. AXGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for SiBone&#39;s 2024 loss per share have remained constant at 89 cents in the past 30 days. Shares of the company have lost 30.4% in the past year against the industry&#39;s 15.5% growth. SIBN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.4%. In the last reported quarter, it delivered an earnings surprise of 15.4%.
<a href="https://www.zacks.com/stock/news/2336320/here-s-why-you-should-add-inogen-stock-to-your-portfolio-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2336320">To read this article on Zacks.com click here.</a>

Biotech

Small Cap

Management

Markets

SIBN

Here's Why You Should Add Inogen Stock to Your Portfolio Now

Inogen, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ingn#NASDAQ">INGN</a>) incurred an adjusted loss per share of 7 cents for the second quarter of 2024, narrower than the adjusted loss per share of 25 cents in the year-ago period. The Zacks Consensus Estimate was pegged at a loss of 54 cents per share.
GAAP loss per share for the quarter was 24 cents, better than the year-earlier loss of 42 cents per share.
<h3>Revenues in Detail</h3>
Inogen registered revenues of $88.8 million for the second quarter, up 6.1% year over year. The figure beat the Zacks Consensus Estimate by 7.8%.
At constant exchange rate (CER), total revenues for the reported quarter increased 6.2%.
Per management, the year-over-year uptick in the top line was primarily driven by higher international and domestic business-to-business sales. However, this was partially offset by lower direct-to-consumer sales and rental revenues.
<h3>Segmental Details</h3>
Inogen derives revenues from two sources &mdash; rental and sales.
Rental revenues for the reported quarter grossed $14.3 million, down 6.5% from the year-ago period, both on a reported basis and at CER. Per management, the decrease resulted from a higher mix of lower private payer reimbursement rates and higher rental revenue adjustments.
Sales revenues were $74.4 million, up 8.9% from the prior-year quarter.
<h3>Revenues by Region &amp; Category</h3>
Domestic business-to-business sales for second-quarter 2024 amounted to $21.3 million, up 16.5% on a year-over-year basis.
International business-to-business sales for the reported quarter amounted to $30.5 million, up 31.1% year over year on a reported basis and up 31.4% at CER.
Domestic direct-to-consumer sales decreased 15.6% year over year to $22.6 million in the quarter. Domestic direct-to-consumer rentals decreased 6.5% year over year to $14.3 million in the quarter.
<h3>Margins</h3>
For the quarter under review, Inogen&#39;s gross profit rose 25.6% from the year-ago period to $42.7 million. The gross margin expanded 740 basis points to 48.1%.
Sales and marketing expenses decreased 4.8% from the year-ago quarter to $25.6 million. Research and development expenses increased 30.2% year over year to $5.6 million. General and administrative expenses increased 27.4% to $18.6 million. Operating expenses of $49.8 million increased 8.7% year over year.
Operating loss totaled $7.1 million compared with the prior-year quarter&#39;s loss of $11.8 million.
<h3>Financial Position</h3>
Inogen exited the second quarter of 2024 with cash and cash equivalents of $98 million compared with $121.2 million at the end of the first quarter of 2024.
The company ended the quarter with no debt on its balance sheet.
Net cash provided by operating activities at the end of the second quarter of 2024 was $1.9 million against net cash used in operating activities of $2.3 million a year ago.
<h3>Guidance</h3>
Inogen provided its revenue outlook for 2024.
The company expects the metric to be between $325 million and $330 million. The Zacks Consensus Estimate currently stands at $322.3 million.
<h3>Our Take</h3>
Inogen exited the second quarter of 2024 with better-than-expected top and bottom-line numbers. The year-over-year improvement on both counts was encouraging. The robust year-over-year uptick in domestic and international business-to-business sales was impressive. The expansion of the gross margin also bodes well.
Inogen announced the launch of its latest Portable Oxygen Concentrator (POC) Rove 4 in the latter half of the year. Rove 4 introduces a fourth flow setting, offers up to eight years of service life and provides the highest oxygen production in the lightest POC on the market. These innovations align with its mission to enhance patient mobility and quality of life during oxygen therapy. With Rove 4, Inogen continues to lead the way in advanced, patient-focused oxygen therapy solutions.
However, the decline in domestic direct-to-consumer sales and rental revenues is concerning. Inogen continued to incur operating losses in the second quarter, which does not bode well.
<div class="chart_embed">
<h3>Inogen, Inc Price, Consensus and EPS Surprise</h3>
<img alt="Inogen, Inc Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/9f/1723036924.png" style="height:265px; width:574px" title="" />
Inogen, Inc price-consensus-eps-surprise-chart | Inogen, Inc Quote
</div>
<h3>Zacks Rank &amp; Key Picks</h3>
Currently, Inogen carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the broader medical space are&nbsp;Universal Health Service,&nbsp;Quest Diagnostics&nbsp;and&nbsp;ABM Industries. While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy) each.
Universal Health Services has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 41.1% compared with the industry&#39;s&nbsp;34.8% rise so far this year.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 3.7% so far this year compared with the&nbsp;industry&#39;s&nbsp;10.2% rise.
ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM&#39;s shares have risen 24.1% so far this year compared with the industry&#39;s&nbsp;11.9% increase.
<a href="https://www.zacks.com/stock/news/2318226/inogen-ingn-q2-earnings-beat-estimates-revenues-rise-y-y?cid=CS-BENZ-FT-analyst_blog|earnings_article-2318226">To read this article on Zacks.com click here.</a>

Inogen Q2 Earnings Beat Estimates, Revenues Rise Y/Y

Press Releases

Inogen Launches Rove 4 Portable Oxygen Concentrator, Delivering the Highest Oxygen Output in the Lightest Weight 4-Setting POC

Inogen to Report Third Quarter 2024 Financial Results on November 7, 2024

Inogen to Present at Upcoming Investor Conferences

Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

Inogen Announces Third Quarter 2024 Financial Results

Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device

Inogen Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

Inogen Expands Product Portfolio, Global Reach and Innovation Pipeline Through Strategic Collaboration With Yuwell

Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

Comments

Inogen

Intérêt court

Inogen (NASDAQ:INGN) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL